Neuroprotection in perinatal hypoxic-ischemic encephalopathy. Effective treatment and future perspectives;Neuroproteccion en la encefalopatia hipoxico isquemica perinatal tratamientos con eficacia clinica demostrada y perspectivas futuras

Medicina

Volumn 67, Issue 6 I, 2007, Pages 543-555

  Legido, Agustin ^a   Valencia, Ignacio ^a   Katsetos, Christos D ^a   Delivoria Papadopoulos, Maria ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Antiepileptic drugs; Hypothermia; Neuroprotection; Opioids; Perinatal hypoxic ischemic encephalopathy

Indexed keywords

ALLOPURINOL; CARBAMAZEPINE; ETIRACETAM; FENTANYL; LAMOTRIGINE; MORPHINE; OPIATE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; ANTICONVULSIVE AGENT; ENZYME INHIBITOR;

BRAIN ISCHEMIA; CLINICAL TRIAL; COMA; DEATH; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; EPILEPTIC STATE; HEART DISEASE; HUMAN; HYPERTHERMIC THERAPY; HYPOPLASTIC LEFT HEART SYNDROME; HYPOTHERMIA; HYPOXIA; INFANT; NEUROPROTECTION; PERINATAL CARE; PROGNOSIS; REVIEW; SEIZURE; ANIMAL; CRYOANESTHESIA; DISEASE MODEL; FORECASTING; NEWBORN;

ALLOPURINOL; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FORECASTING; HUMANS; HYPOTHERMIA, INDUCED; HYPOXIA-ISCHEMIA, BRAIN; INFANT, NEWBORN;

EID: 38449089224     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Valencia I, Legido A. Prevention of epilepsy. En: Benjamin SM (ed). Focus on epilepsy research. Hauppauge: Nova Biomedical Books, 2004, p.1-21.
2. Vajda FJ. Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002; 9:4-8.
3. Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 2001; 7: 56-64.
4. Legido A. Perinatal hypoxic-ischemic encephalopathy: current advances in diagnosis and treatment. Int Pediatr 1994; 9: 114-36.
5. Legido A. Pathophysiology of perinatal hypoxic-ischemic encephalopathy. Acta Neuropediatr 1994; 1: 97-110.
6. Johnston MV. Excitotoxicity in perinatal brain injury. Brain Pathol 2005; 15: 234-40.
7. Delivoria-Papadopoulos M, Mishra OP. Mechanisms of cerebral injury in perinatal asphyxia and strategies for prevention. J Pediatr 1998; 132 (3 Pt 2): 30-4.
8. Jensen A, Garnier Y, Middelanis J, Berger R. Perinatal brain damage-from pathophysiology to prevention. Eur J Obstet Gynecol Reprod Biol 2003; 110 (Supl 1): 70-9.
9. Legido A, Katsetos CD, Mishra OP, Delivoria-Papadopoulos M. Perinatal hypoxic-ischemic encephalopathy: Current and future treatments. Int Pediatr 2000; 15: 143-51.
10. Johnston MV, Trescher WH, Ishida A, Nakajima W. Novel treatments after experimental brain injury. Semin Neonatol 2000; 5: 75-86.
11. Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 1997; 100: 1004-11.
12. Whitelaw A, Thoresen M. Clinical trials of treatments after perinatal asphyxia. Curr Opin Pediatr 2002; 14: 664-8.
13. Perlman JM. Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin Ther 2006; 28: 1353-65.
14. Perlman JM. Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics 2006; 117 (3 Pt2): 28-33.
15. Clancy RR, McGaurn SA, Goin JE, Hirtz DG, Norwood Wl, Gaynor JW, et al. allopurinol neurocardiac protection trial in infants undergoing heart surgery using deep hypothermic circulatory arrest. Pediatrics 2001; 108: 61-70.
16. Tan S, Parks DA. Preserving brain function during neonatal asphyxia. Clin Perinatol 1999; 26: 733-47.
17. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. Pediatr Res 1990; 27 (4 Pt1): 3322-6.
18. Marro PJ, Andersen CB, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on hypoxia-induced modification of the NMDA receptor in newborn piglets. Neurochem Res 1999; 24: 1301-6.
19. Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 2006; 1073-74: 444-50.
20. Russell GA, Cooke RW. Randomized controlled trial of allopurinol prophylaxis in very preterm infants. Arch Dis Child Fetal Neonatal Ed 1995; 73: F27-31.
21. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics 1998; 101: 185-93.
22. Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al. Erly postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fenatl Neonatal Ed 2006; 91: F163-5.
23. Lee J, Kim MS, Park C, Jung EB, Choi DH, Kim TY, et al. Morphine prevents glutamate-induced death of primary rat neonatal astrocytes through modulation of intracellular redox. Immunopharmacol Immunotoxicol 2004; 26: 17-28.
24. Yamakura T, Sakimura K, Shimoji K. Direct inhibition of the N-methyl-D-aspartate receptor channel by high concentration of opioids. Anesthesiology 1999; 91: 1053-63.
25. Zhang J, Gibney GT, Zhao P, Xia Y. Neuroprotective role of delta-opioid receptors in cotrical neurons. Am J Physiol 2002; 282: C1225-34.
26. Zhang J, Haddad GG, Xia Y. Delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury. Brain Res 2000; 8856: 143-53.
27. Lim YJ, Zheng S, Zuo Z. Morphine preconditions Purkinje cells against cell death under in vitro simulated ischemia-reperfusion conditions. Anesthesiology 2004; 100: 562-8.
28. Mayfield KP, D'Alecy LG. Role of endogenous opioid peptides in the acute adaptation to hypoxia. Brain Res 1992; 582: 226-31.
29. Mayfield KP, D'Alecy LG. Delta-1 opioid agonist acutely increases hypoxic tolerance. J Pharmacol Exp Ther 1994; 268: 683-8.
30. Chien S, Oeltgen PR, Diana JN, Salley RK, Su TP. Extension of tissue survival time in multiorgan block preparation with a delta DADLE ([D-Ala2, D-leu5]-enkephalin). J Thorac Cardiovasc Surg 1994; 107: 964-7.
31. Angeles DM, Wycliffe N, Michelson D, Holshouser BA, Deming DG, Pearce WJ, et al. Use of opioids in asphyxiated term neonates: effects of neuroimaging and clinical outcome. Pediatr Res 2005; 57: 873-8.
32. Gunn AJ. Cerebral hypothermia for prevention of brain injury following perinatal asphyxia. Curr Opin Pediatr 2000; 1: 111-5.
33. Gunn AJ, Battin M, Gluckman PD, Gunn TR, Bennet L. Therapeutic hypothermia: from lab to NICU. J Perinat Med 2005; 33: 340-6.
34. Gunn AJ, Thoresen M. Hypothermic neuroprotection. NeuroRx 2006; 3: 154-69.
35. Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics 1998; 102: 885-92.
36. Battin MR, Dezoete JA, Gunn TR, Gluckman PD, Gunn AJ. Neurodevelopmental outcome of infants treated with head cooling and mild hypothermia after perinatal asphyxia. Pediatrics 2001; 107: 480-4.
37. Battin MR, Penrice J, Gunn TR, Gunn AJ. Treatment of terra infants with head cooling and systemic hypothermia (35.0 degrees C and 34.5 degrees C) after perinatal asphyxia. Pediatrics 2003; 111: 244-51.
38. Gluckman PD, Wyatt JS, Azzopardi D, Ballard D, Edwards AD, Ferriero DM, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicenter randomized trial. Lancet 2005; 365: 663-70.
39. Azzopardi D, Robertson NJ, Cowan FM, Rutherford MA, Rampling M, Edwards AD. Pilot study of treatment with whole body hypothermia for neonatal encephalopathy. Pediatrics 2000; 106: 684-94.
40. Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, et al. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for randomized, controlled pilot study in term infants. Pediatrics 2002; 110: 377-85.
41. Compagnoni G, Pogliani L, Lista G, Castoldi F, Fontana P, Mosca F. Hypothermia reduces neurological damage in asphyxiated newborn infants. Biol Neonate 2002; 82: 222-7.
42. Debillon T, Daoud P, Durand P, Cantagel S, Jouvet P, Saizou C, et al. Whole-body cooling after perinatal asphyxia: a study in term neonates. Dev Med Child Neurol 2003; 45: 17-23.
43. Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, et al. Moderate hypothermia in neonatal encephalopathy: safety outcomes. Pediatr Neurol 2005; 32: 18-24.
44. Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, et al. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol 2005; 32: 11-7.
45. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med 2005; 353: 1574-84.
46. Shankaran S, Laptook A. Challenge of conducting trials of neuroprotection in the asphyxiated term infant. Semin Perinatol 2003; 27: 320-32.
47. Wyatt JS, Robertson NJ. Time for a cool head-neuroprotection becomes a reality. Early Hum Dev 2005; 81: 5-11.
48. Edwards AD, Azzopardi DV. Therapeutic hypothermia following asphyxia. Arch Dis Fetal Neonatal Ed 2006; 91: F127-31.
49. Wagner BP, Nedelcu J, Martin E. Delayed postischemic hypothermia improves long-term behavioral outcome after cerebral hypoxia-ischemia in neonatal rats. Pediatr Res 2002; 51: 354-60.
50. Ma D, Hossain M, Chow A, Arshad M, Battson RM, Sanders RD, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. Ann Neurol 2005; 58: 182-93.
51. Iwata O, Thornton JS, Sellwood MW, Iwata S, Sakata Y, Noone MA, et al. Depth of delayed cooling alters neuroprotection pattern after hypoxia-ischemia. Ann Neurol 2005; 58: 75-87.
52. Kanagawa T, Fukuda H, Tsbouchi H, Komoto Y, Hayashi S, Fukui O, et al. A decrease of cell proliferation by hypothermia in the hippocampus of the neonatal rat. Brain Res 2006; 1111: 36-40.
53. Hoeger H, Engidawork E, Stolzlechner D, Bubna-Littitz H, Lubec B. Long-term effect of moderate and profound hypothermia on morphology, neurological, cognitive and behavioural functions in a rat model of perinatal asphyxia. Amino Acids 2006; 31: 385-96.
54. Talati AJ, Yang W, Yolton K, et al. Combination of early perinatal factors to identify near-term and term neonates for neuroprotection. J Perinatol 2005; 25: 245-50.
55. Ambalavanan N, Carlo WA, Shankaran S, Bann CM, Emrich SL, Higgins RD, et al. Predicting outcomes of neonates diagnosed with hypoxemic-ischemic encephalopathy. Pediatrics 2006; 118: 2084-93.
56. Schifrin BS, Ater S. Fetal hypoxic and ischemic injuries. Curr Opin Obstet Gynecol 2006; 18:112-22.
57. Higgins RD, Rahu TN, Perlman J, Azzopardi DV, Blackmon LR, Clark RH, et al. Hypothermia and perinatal asphyxia: executive summary of the National Institute of Child Health and Human Development workshop. J Pediatr 2006; 148: 170-5.
58. Moshé SL. Neuroprotection and epilepsy. Medscape 2000; http://www.medscape.com, January 19:1-12.
59. Pitkänen A. Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res 2002; 50: 141-60.
60. Calabresi P, Cupini LM, Centonze D, et al. Antiepileptic drugs as a possible neuroprotective strategy in ischemia. Ann Neurol 2003; 53: 693-702.
61. Leker RR, Neufeld MY. Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia. Brain Res Brain Res Rev 2003; 42: 187-203.
62. Sankar R. Neuroprotection in epilepsy: the Holy Grall of antiepileptic therapy. Epilepsy Behav 2005; 7 (Suppl 3): S1-2.
63. Wilmore LJ. Antiepileptic drugs and neuroprotection: current status and future roles. Epilepsy Behav 2005; 7 (Suppl 3): S25-8.
64. Wyllie E, Gupta A, Lachhwani DK (eds). The treatment of epilepsy. Principles and practice. Philadelphia: Lippincott Williams & Wilkins, 2006.
65. Hertz E, Shargool M, Hertz L. Effects of barbiturates on energy metabolism by cultured astrocytes and neurons in the presence of normal and elevated concentrations of potassium. Neuropharmacology 1986; 25: 533-9.
66. Sutula T, Cavazos J, Golarai G. Alteration of long-lasting structural and functional effects of kalnic acid in the hippocampus by brief treatment with phenobarbital. J Neurosci 1992; 12: 4173-87.
67. Rekling JC. Neuroprotective effects of anticonvulsants in rat hippocampal slice cultures exposed to oxygen/glucose deprivation. Neurosci Lett 2003; 335: 167-70.
68. Mikati MA, Holmes GL, Chronopoulos A, Hyde P, Thurber S, Gatt A, et al. Phenobarbital modifies seizure-related Brain injury in the developing brain, Ann Neurol 1994; 36: 425-33.
69. Bolanos AR, Sarlisian M, Yang Y, Pavone A, Maci T, Perciavalle V. Comparison of valproate and phenobarbital treatment alter status epilepticus in rats. Neurology 1998; 51: 41-8.
70. Diaz J, Schain RJ, Balley BG. Phenobarbital-induced brain growth retardation in artificially reared rat pups. Biol Neonate 1977; 32: 77-82.
71. Jacobson CD, Antolick LL, Schoiley R, Uemura E. The influence of prenatal phenobarbital on the growth of dendrites in the rat hippocampus. Brain Res Dev Brain Res 1988; 44: 233-9.
72. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann NY Acad Sci 2003; 993: 103-14.
73. Hall RT, Hall FK, Daily DK. High-dose Phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. J Pediatr 1998; 132: 345-8.
74. Singh D, Kumar P, Majumdar S, Narang A. Effect of Phenobarbital on free radicals in neonates with hypoxic ischemic encephalopathy-a randomized controlled trial. J Perinat Med 2004; 43: 278-81.
75. Vargas-Origel A, Espinosa-Gamia JO, Muñiz-Quezada E, Vargas-Nieto MA, Aguilar-Garcia G. Prevención de la encefalopatía hipóxico-isquémica con dosis altas, precoces de fenobarbital. Gac Med Mex 2004; 140: 147-53.
76. Farwell JR, Lee JY, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence. N Engl J Med 1990; 322: 364-9.
77. Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann JM. Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents. Neurosci Lett 1994; 172: 19-23.
78. Hayakawa T, Amada Y, Maihara T, Hattoti H, Mikawa H. Phenytoin reduces neonatal hypoxic-ischemic brain damage in rats. Life Sci 1994; 54: 387-92.
79. Vartanian MG, Cordon J J, Kupina NC, et al. Phenytoin pretreatment prevents hypoxic-ischemic brain damage in neonatal rats. Brain Res Der Brain Res 1996; 95:169-75.
80. Chan SA, Reid KH, Schurr A, Miller J J, Iyer V, Tseng MT. Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir (Wien) 1998; 140: 175-80.
81. Weber ML, Taylor CP. Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials. Brain Res 1994; 664:167-77.
82. Kaptanoglou E, Solaroglu I, Surucu HS, Akbiyik F, Beskonakli E. Blockade of sodium channels by phenytoin protects ultrastructure and attenuates lipid peroxidation in experimental spinal cord injury. Acta Neurochir (Wien) 2005; 147: 405-12.
83. Dong LP, Wang TY, Zhu J. Effects of carbamazepine on hypoxic and ischemic damage in mice. Zhongguo Yao Li Xue Bao 1994; 15: 257-9.
84. Minato H, Kikuta C, Fujitani B, Masuda Y. Protective etfect of zonisamide, and antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 1997; 38: 975-80.
85. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The actrivity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-44.
86. Jeong MR, Hashimoto R, Senatorov VV, et al. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett 2003; 542: 74-8.
87. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006; 26: 7502-12.
88. Kabakus N, Ay I, Aysun S, Soylemezoglu F, Ozcan A, Celasun B. Protective effects of valproic acid against hypoxic-ischemic brain injury in neonatal rats. J Child Neurol 2005; 20: 582-7.
89. Thurston JH, Hauhart RE. Valproate doubles the anoxic survival time of normal developing mice: possible relevance to valproate-induced decreases in cerebral levels of glutamate and aspartate, and increases in taurine. Life Sci 1989; 45: 59-62.
90. Brandt C, Gastens AM, Sun M, Hauknecht M, Loscher W. Treatment with valproate after status epilepticus: effect on neuronal damage, epilpeptogenesis, and behavioral alterations in rats. Neuropharmacology 2006; 51: 789-804.
91. Williams JA, Barreiro CJ, Nwakanma KU, et al. Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery. Ann Thorac Surg 2006; 81: 2235-41.
92. Mora A, González-Polo RA, Fuentes JM, Soler G, Centeno F. Different mechanisms of protection against apoptosis by valproate and Li+. Eur J Biochem 1999; 266: 886-91.
93. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005; 1053: 195-204.
94. Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid mediated Hsp70 induction and anti-apoptotoc neuro-protection in SH-SY5Y cells. FEBS Lett 2005; 579: 6716-20.
95. Klitgaard HV, Matagne AC, Vanneste-Goemare J, Margineanu DG. Effects of prolonged administration of levetiracetam on pilccarpine-induced epileptogenesis. Epilepsia 2001; 42 (Supl 7): 114-5.
96. Traystman RJ, Klaus JA, DeVries AC, Shaivitz AB, Hum PD. Anticonvulsant lamotrigine administered on reperfusion fails to improve experimental stroke outcomes. Stroke 2001; 32: 783-7.
97. Lee WT, Shen YZ, Chang C. Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3-nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic spectroscopy. Neuroscience 2000; 95: 89-95.
98. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117-21.
99. Wiard RP, Dickerson MC, Beek O, Norton R, Cooper BR. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke 1995; 26: 466-72.
100. Shuaib A, Mahmood RH, Wishart T, Kanthan R, Murabit MA, Ijaz S, et al. Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioural study. Brain Res 1995; 702: 199-206.
101. Crumrine RC, Bergstrand K, Cooper AT, Faison WL, Cooper BR. Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest. Stroke 1997; 28: 2230-7.
102. Lee YS, Yoon BW, Roth JK. Neuroprotective effect of lamotrigine enhanced by flunarizine in gerbil global ischemia. Neurosci Lett 1999; 265: 215-7.
103. Koinig H, Morimoto Y, Zomow MH. The combination of lamotrigine and mild hypothermia prevents ischemia-induced in hippocampal glutamate. J Neurosurg Anesthesiol 2001; 13: 106-12.
104. Yang Y, Shuaib B, Li Q, Siddiqui MS. Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998; 804: 169-76.
105. Yang Y, Li Q, Miyashita H, Howlett W, Siddiqui M, Shuaib A. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. J Neurosurg 2000; 92: 841-7.
106. Lee SR, Kim SOP. Kim JE. Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett 2000; 281: 183-6.
107. Niebauer M, Gruenthal M. Toipiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999; 837: 263-9.
108. Koh S, Jensen FE. Topiramate blocks perinatal hypoxia-induced seizures in rat pups. Ann Neurol 2001; 50: 366-72.
109. Schubert S, Brandl U, Brodhun M, et al. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res 2005; 1958: 129-36.
110. Follett PL, Deng W, Dai W, et al. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J Neurosci 2004; 24: 4412-20.
111. Sfaello I, Baud O, Arzimanoglou A, Gressens P. Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiol Dis 2005; 20: 837-48.
112. Glier C, Dzietto M, Bittigqau P, Jarosz B, Korobowicz E, Ikomidou C. Therapeutic doses of topiramate are not toxic to the developing brain. Exp Neurol 2004; 187: 403-9.
113. Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res 1997; 770: 115-22.
114. Hayakawa T, Higuchi Y, Nigami H, Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsant effect. Eur J Pharmacol 1994; 257: 131-6.
115. Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001; 10: 287-93.
116. Kim DH, Zhao X, Tu CH, Casaccia-Bonnefil P, Chao MV. Prevention of apoptotic but not necrotic injury by neurotrophins signaling through the tyrosine kinase receptor. J Neurosurg 2004; 100: 79-87.
117. Brywe KG, Mallard C, Gustqvsson M, et al. IGF-I neuroprotection in the immature brain after hypoxic-ischemia, involvement of Akt and GSK3beta? Eur J Neurosci 2005; 21: 1489-502.
118. Russell JC, Szuflita N, Khatri R, Laterra J, Hossain MA. Transgenic expression of human FGF-1 protects against hypoxic-ischemic injury in perinatal brain by intervening at caspase-XIAP signaling cascades. Neurobiol Dis 2006; 22: 677-90.
119. Lin CH, Cheng FC, Lu YZ, Chu LF, Wang CH, Hsueh CM. Protection of ischemic brain cells is dependent on astrocyte-derived growth factors and their receptors. Exp Neurol 2006; 201: 225-33.
120. Galvin KA, Oorschot DE. Continuous low dose treatment with brain-derived neurotrophic factor or neurotrophin-3 protects striatal medium spiny neurons from mild neonatal hypoxia/ischemia: a stereological study. Neuroscience 2003; 118: 1023-32.
121. Chiaretti A, Genovese O, Riccardi R, et al. Intraventricular nerve growth factor infusion: a possible treatment for neurological deficits following hypoxic-ischemic brain injury in infants. Neurosci Res 2005; 27: 741-6.
122. Katsurtagi S, Ikeda T, Date I, Shingo T, Yasuhara T, Ikenoue T. Grafting of glial cell line-derived neurotrophic factor secreting cells for hypoxic-ischemic encephalopathy in neonatal rats. Am J Obstet Gynecol 2005; 192: 1137-45.
123. Tabakman R, Jiang H, Shahar I, Arien-Zakay H, Levine RA, Lazarovici P. Neuroprotection by NGF in the PC12 in vitro OGD model: involvement of mitogen-activated protein kinases and gene expression. Ann N Y Acad Sci 2005; 1053: 84-96.
124. Aguilar LC, Islas A, Rosique P, Hernández B, Portillo E, Herrera JM, et al. Psychometric analysis in children with mental retardation due to perinatal hypoxia treated with fibroblast growth factor (FGF) and showing improvement in mental development. J Intellect Disabil Res 1993; 37: 507-20.
125. Millan M, Arenillas J. Gene expression in cerebral ischemia: a new approach for neuroprotection. Cerebrovasc Dis 2006; 21 (Supl 2) 30-7.
126. Yenari MA, Minami M, Huan Sun G, et al. Calbindin D28K overexpression protects striatal neurons from transient focal cerebral ischemia. Stroke 2001; 32: 1028-35.
127. Linnik MD, Zahos P, Geschwind MD, Federoff HJ. Expression of bcl2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995; 26: 1670-4
128. Jia WW, Wang Y, Qiang D, Tufaro F, Remingston R, Cynader M. A bcl-2 expressing viral vector protects cortical neurons from excitotoxicity even when administered several hours after the toxic insult. Brain Res Mol Brain Res 1996; 42: 350-3
129. Sasaki T, Kitagawa K, Yagita Y, et al. Bcl2 enhances survival of newborn neurons in the normal and ischemic hippocampus. J Neurosci Res 2006; 84: 1187-96.
130. Shen F, Su H, Fan Y, Chen Y, et al. Adeno-associated viral vector mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice. Stroke 2006; 37: 2601-6.
131. Tal YT, Svendsen CN. Stem cells as a potential treatment of neurological disorders. Curr Opin Pharmacol 2004; 4: 98-104.
132. Longhi L, Zanier ER, Royo N, Stocchetti N, McIntosh TK. Stem cell transplantation as a therapeutic strategy for traumatic brain injury. Transpl Immunol 2005; 15: 143-8.
133. Qu SQ, Luan Z, Yin GC, et al. Transplantation of human fetal neural stem cells into cerebral ventricle of the neonatal rat following hypoxic-ischemic injury: survival, migration and differentiation. Zhonghua Er Ke Za Zhi 2005; 43: 576-9.
134. Zheng T, Rossignol C, Leibovici A, Anderson KJ, Steindler DA, Weiss MD. Transplantation of multipotent astrocytic stem cells into a rat model of neonatal hypoxicischemic encephalopathy. Brain Res 2006; 1112: 99-105.
135. Yasuhara T, Matsukawa N, Yu G, Xu L, Mays RW, Kovach J, et al. Transplantation of cryopreserved human bone marrow-derived multipotent adult progenitor cells for neonatal hypoxic-ischemic injury: targeting the hippocampus. Rev Neurosci 2006; 17: 215-25.
136. Jensen A, Valhinger HM, Meier C. [Perinatal brain damage-from neuroprotection to neurodegeneration using cord blood stem cells]. Med Klin (Munich) 2003; 98 (Supl 2): 22-6.
137. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 2004; 35: 2385-9.
138. Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006; 59: 244-9.
139. Ang BT, XU G, Xiao ZC. Therapeutic vaccination for central nervous system repair. Clin Exp Pharmacol Physiol 2006; 33: 541-5.
140. During MJ, Symes CW, Lawlor PA, Lin J, Dunning J, Fitzsimons HL, et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 2000; 287: 1453-60.